Meeting Banner
Abstract #1645

T2 Monitoring at 3T for Canine Model of Duchenne Muscular Dystrophy

Donghoon Lee1, Zejing Wang2, Joshua Park1, Stephen Tapscott2, Martin Kushmerick1

1University of Washington, Seattle, WA, United States; 2Fred Hutchinson Cancer Research Center, Seattle, WA, United States

Gene therapy is one of promising treatment approaches for Duchenne muscular dystrophy. One challenge is to noninvasively monitor treatment responses and thereby to evaluate treatment efficacy. Canine MR imaging was conducted to noninvasively monitor muscle changes due to disease progression and to assess the treatment response after adeno-associated virus (AAV) vector mediated gene therapy. Elevation of T2 was observed for dystrophic muscles comparing to normal muscles and reduction of T2 was monitored for the treated muscles. The results show T2 would be a potential MR marker to study muscle integrity and the treatment efficacy.

Abstract PDF Poster PDF

Keywords

able adductor affected although anterior assess assessments biceps cancer canine cellular clinical coil common comparing conducted control covering cure decrease dependent detected diagnostic dimensional disease disorders dogs dystrophy echoes efficacy eight element enables evaluate fatty five flex flexible forms future gene generate goal golden good gradient homogeneous humans identify infiltration inflammatory inherited injecting involvement lack limb linked litter marker martin massively measured mechanisms mediated medicated miller model monitor monitoring muscle muscles muscular nerve neuromuscular noninvasive opposed pane park past patients practice processes quantification quantify quantitative ranging reduction representative respectively responses retriever sense sensitivity served signs slightly smaller software spin stages statistical summarized surface therapeutic therapy treated treatment turbo untreated upper useful various vector version virus wide